Antioxidants and muscle atrophy in colon cancer: beneficial or deleterious effects?
Cancer cachexia is a multifactorial syndrome characterized by an ongoing loss of body weight, mainly due to adipose tissue and skeletal muscle wasting. Muscle atrophy leads to a progressive functional impairment and contributes to a negative impact on patient's quality of life. Oxidative Stress (OS) seems to play a major role in muscle atrophy since OS markers are increased in plasma and muscles of cancer patients. Thus, supplementing patients with antioxidant may reduce OS and restore muscle mass and function. In this study, we assess the effects of antioxidant supplementation on muscle atrophy in a model of colon 26 tumor-bearing mice (C26-mice). Five-week old Balb/c mice receive a subcutaneous injection of PBS or C26 cancer cells with or without daily supplementation with Allopurinol or Oxynov (50mg/kg and 163mg/kg respectively). Blood and muscles are removed 20-22 days after injection. C26-mice develop cachexia, with a decrease in total body weight, muscular endurance and muscle fibers diameter. Furthermore, injection of C26 induces ubiquitination of muscles proteins, suggesting the enhancement of muscle proteolysis. Contrary to our expectations, supplementation with antioxidants (Allopurinol or Oxynov) doesn't prevent weight loss and muscle atrophy but induces premature death of mice. C26-mice exhibit systemic oxidative stress markers (i.e. carbonyl proteins and 4-HNE) and show an increase in phosphorylation levels of the redox-dependent kinase, JNK, in the atrophied muscles (i.e. gastrocnemius). Surprisingly, Allopurinol or Oxynov decrease the total antioxidant defenses in plasma but has no effect on C26-induced oxidative damages and JNK phosphorylation. Our results are in agreement with recent reports showing deleterious effects of antioxidants supplementation in lung and prostate cancer. However, such findings require further investigations.